ph-0497
print Print Back Back

Beovu (brolucizumab-dbll)

Policy Number: PH-0497

Intravitreal

 

Last Review Date: 10/28/2019

Date of Origin: 10/28/2019

Dates Reviewed: 11/2019

  1. Length of Authorization

Coverage will be provided annually and may be renewed.

  1. Dosing Limits

          A.  Quantity Limit (max daily dose) [NDC Unit]:

  • 6 mg single-use vial for injection: 1 vial per eye every 25 days

          B.  Max Units (per dose and over time) [HCPCS Unit]:

Diagnosis

MU for Initial Dosing

MU for Maintenance Dosing

Neovascular age-related macular degeneration (AMD)

12 billable units every 25 days x 3 doses

12 billable units every 56-84 days

(Max units are based on administration to both eyes)

  1. Initial Approval Criteria1

Coverage is provided in the following conditions:

  • Patient is 18 years or older; AND
  • Patient is free of ocular and/or peri-ocular infections; AND
  • Patient does not have active intraocular inflammation; AND
  • Therapy will not be used with other ophthalmic VEGF inhibitors (i.e., aflibercept, ranibizumab, pegaptanib, bevacizumab, etc.) ; AND
  • Patient has baseline measurement of the best corrected visual acuity (BCVA); AND
  • Patient has a definitive diagnosis of the following:
    • Neovascular (Wet) Age-Related Macular Degeneration (AMD) †

     † FDA Approved Indication(s)

  1. Renewal Criteria1

Coverage can be renewed based upon the following criteria:

  • Patient continues to meet the criteria identified in section III; AND
  • Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: endophthalmitis and retinal detachments; increase in intraocular pressure; arterial thromboembolic events; AND
  • Patient has had a beneficial response to therapy (e.g., improvement in the baseline best corrected visual acuity (BCVA), etc.); AND
  • Continued administration is necessary for the maintenance treatment of the condition
  1. Dosage/Administration

Indication

Dose

AMD

The recommended dose for Beovu is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25-31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks.

  • For many patients, dosing at the every 12 week frequency is sufficient. For some patients who show continued disease activity, increasing the frequency to every 8 weeks may be considered.
  • Decreasing the interval of maintenance doses from 12-weeks to 8-weeks will be allowed if the patient has received all three loading doses and has evidence of disease activity, indicated by one of the following, at (or beyond) treatment-week 16:
  • Decrease in BCVA of ≥ 5 letters compared to baseline; OR
  • Decrease in BCVA of ≥ 3 letters and central subfield thickness ≥ 75 µm compared with week 12; OR
  • Decrease in BCVA of ≥ 5 letters due to neovascular AMD disease activity compared with week 12; OR
  • New or worsening intra-retinal cysts or fluid compared with week 12
  1. Billing Code/Availability Information

HCPCS:

J3590 – Unclassified biologic drug

J0179 – Injection, brolucizumab-dbll, 1 mg; 1 mg = 1 billable unit (effective 1/1/2020)

NDC:

Beovu 6 mg/0.05 mL Solution for Injection, single-use vial: 00078-0827-xx

  1. References

          1.  Beovu [package insert].  East Hanover, NJ; Novartis Pharmaceuticals, Inc.; October 2019. Accessed October 2019.

          2.  Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.                                       Ophthalmology. 2019 Apr 12. pii: S0161-6420(18)33018-5.

          3.  Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296e1304.

          4.  Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Mar; 40(3):412-418.

          5.  American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Panel, Hoskins Center for Quality Eye Care. Diabetic Retinopathy PPP – Update 2017. Nov 2017.

          6.  American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Panel, Hoskins Center for Quality Eye Care. Retinal Vein Occlusions PPP – Update 2017. Nov 2017.

          7.  American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Panel, Hoskins Center for Quality Eye Care. Age-Related Macular Degeneration PPP – Update 2017.                   Nov 2017.

          8.  Royal College of Ophthalmologists. Clinical Guidelines – Retinal Vein Occlusion (RVO) Guidelines – July 2015. Accessed at https://www.rcophth.ac.uk/standards-publications-research/clinical-                           guidelines.

Appendix 1 – Covered Diagnosis Codes

ICD-10

ICD-10 Description

H35.3210

Exudative age-related macular degeneration, right eye, stage unspecified

H35.3211

Exudative age-related macular degeneration, right eye, with active choroidal neovascularization

H35.3212

Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization

H35.3213

Exudative age-related macular degeneration, right eye, with inactive scar

H35.3220

Exudative age-related macular degeneration, left eye, stage unspecified

H35.3221

Exudative age-related macular degeneration, left eye, with active choroidal neovascularization

H35.3222

Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization

H35.3223

Exudative age-related macular degeneration, left eye, with inactive scar

H35.3230

Exudative age-related macular degeneration, bilateral, stage unspecified

H35.3231

Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization

H35.3232

Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization

H35.3233

Exudative age-related macular degeneration, bilateral, with inactive scar

H35.3290

Exudative age-related macular degeneration, unspecified eye, stage unspecified

H35.3291

Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization

H35.3292

Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization

H35.3293

Exudative age-related macular degeneration, unspecified eye, with inactive scar

H35.81

Retinal edema

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction

Applicable State/US Territory

Contractor

E (1)

CA, HI, NV, AS, GU, CNMI

Noridian Healthcare Solutions, LLC

F (2 & 3)

AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ

Noridian Healthcare Solutions, LLC

5

KS, NE, IA, MO

Wisconsin Physicians Service Insurance Corp (WPS)

6

MN, WI, IL

National Government Services, Inc. (NGS)

H (4 & 7)

LA, AR, MS, TX, OK, CO, NM

Novitas Solutions, Inc.

8

MI, IN

Wisconsin Physicians Service Insurance Corp (WPS)

N (9)

FL, PR, VI

First Coast Service Options, Inc.

J (10)

TN, GA, AL

Palmetto GBA, LLC

M (11)

NC, SC, WV, VA (excluding below)

Palmetto GBA, LLC

L (12)

DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)

Novitas Solutions, Inc.

K (13 & 14)

NY, CT, MA, RI, VT, ME, NH

National Government Services, Inc. (NGS)

15

KY, OH

CGS Administrators, LLC

 

BEOVU® (brolucizumab-dbll) Prior Auth Criteria
Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2019, Magellan Rx Management

White MRx.PNG